Qiagen N.V.
Rank #343Capital ReturnQGEN · NYSE · Healthcare
Qiagen N.V. (QGEN) — Rank #343 by gross profitability (GP/assets 0.21) · ROE 11.2% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0001015820 · all metrics point-in-time as of the filing date.
About
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Show moreShow less
The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors.
The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- State
- P7
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- qiagen.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-03-20 | 2024-12-31filed 2025-03-31 | 2023-12-31filed 2024-03-11 | 2022-12-31filed 2023-03-13 |
|---|---|---|---|---|
| Revenue | 2,090.0 | 1,978.2 | 1,965.3 | 2,141.5 |
| Revenue growth (YoY) | 5.7% | 0.7% | -8.2% | -4.9% |
| Cost of revenue | 790.5 | 1,010.9 | 731.6 | 757.0 |
| Gross profit | 1,299.5 | 967.4 | 1,233.7 | 1,384.6 |
| Gross margin | 62.2% | 48.9% | 62.8% | 64.7% |
| Operating income | 465.9 | 97.7 | 409.9 | 531.5 |
| Operating margin | 22.3% | 4.9% | 20.9% | 24.8% |
| Interest income | 64.3 | 68.0 | 79.0 | 32.8 |
| Interest expense | — | — | 53.4 | 58.4 |
| Pre-tax income | 490.3 | 121.1 | 429.8 | 512.6 |
| Income tax expense | 65.4 | 37.6 | 88.5 | 89.4 |
| Net income | 424.9 | 83.6 | 341.3 | 423.2 |
| Net margin | 20.3% | 4.2% | 17.4% | 19.8% |
| EPS (basic) | $1.96 | $0.38 | $1.50 | $1.86 |
| EPS (diluted) | $1.94 | $0.37 | $1.48 | $1.84 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?